Fast Five Quiz: C3G Management

A. Brent Alper, Jr, MD, MPH


April 24, 2023

Unless there are specific contraindications, most patients with C3G should receive therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as first-line therapy for proteinuria and hypertension. Both classes of agents have been effective in other glomerular diseases in slowing progression to renal failure. Additional measures include considering statin therapy to achieve target cholesterol and low-density lipoprotein cholesterol goals. Once supportive care is in place, the benefit of appropriate immunosuppressive therapy, if any, is evaluated. Generally, patients who receive any kind of immunosuppression achieve better outcomes than do patients who are treated conservatively with supportive care only.

There is currently no solid evidence regarding the efficacy of plasma therapy in the treatment of C3G.

Learn more about ACE inhibitors and ARBs for patients with C3G.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.